Impact of Non-Fixed Versus 6 Month Fixed Retreatment Schedules on Serum Immunoglobulins Following Rituximab in Patients with Rheumatoid Arthritis

نویسندگان

  • Inmaculada de la Torre
  • Maria J Leandro
  • Delia Gerona
  • Lara Valor
  • Luis Carreno
چکیده

Results: The percentages of patients developing low IgG or IgM did not differ between groups after the 3rd cycle, but those with non-fixed retreatment tended to be higher. After 4 cycles, median IgM levels were significantly lower in both groups compared with pretreatment (p<0.05). Only patients in the fixed retreatment group receiving 4 cycles of treatment showed a significant drop in median IgG level (p<0.05). IgA levels remained within the normal range. Withdrawals due to infections per 100 patient years (py)s in patients with low IgG were higher after 3 Cycles in patients within the fixed retreatment group (4.60/100py vs 1.36/100py, CI: 0.59, 6.23). DAS28 did not differ between cohorts after multiple cycles.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis

INTRODUCTION In the present study we evaluated changes in the B cell phenotype in peripheral blood and bone marrow (BM) of patients with rheumatoid arthritis (RA) following anti-CD20 treatment using rituximab. METHODS Blood and BM samples were obtained from 37 patients with RA prior to rituximab treatment. Ten of these patients were resampled 1 month following rituximab, 14 patients after 3 m...

متن کامل

Durable remission of pemphigus with a fixed-dose rituximab protocol.

IMPORTANCE Rituximab induces B-lymphocyte apoptosis by targeting CD20 antigen and has shown efficacy in antibody-mediated autoimmune disease. Rituximab is increasingly being acknowledged as an effective and safe treatment option for pemphigus. OBJECTIVE To assess the clinical response of patients with pemphigus to rituximab using a modified fixed-dose rheumatoid arthritis protocol (1 g intrav...

متن کامل

Effect of D-penicillamine on serum immunoglobulins and rheumatoid factor.

Penicillamine has been used in the treatment of patients with rheumatoid arthritis with variable clinical response (Jaffe, 1963; Camus, Guillien, Crouzet, Schaeffer, and Lievre, 1970; Zuckner, Ramsey, Dorner, and Gantner, 1970; Golding, Wilson, and Day, 1970). Moreover, observations on the effect of this drug on serum immunoglobulins and rheumatoid factor titres have yielded conflicting and ind...

متن کامل

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

INTRODUCTION This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab. METHODS All Belgian rheumatologists had the possibility to participate in the study. Patients entered the registry in November 2006 and th...

متن کامل

Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.

OBJECTIVE To evaluate the safety and effectiveness of rituximab (RTX) in combination with methotrexate in patients with active rheumatoid arthritis (RA) after failure of a single tumor necrosis factor-α (TNF-α) inhibitor. Changes in patient-reported outcomes after primary treatment or retreatment with RTX and factors determining retreatment in clinical practice were also evaluated. METHODS In...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2013